Cited by 186Melanoma and MAPK PathwaysProtein Kinase Regulation and GTPase SignalingProtein Tyrosine Phosphatases

The DOI matches its Crossref record; 68 of the 74 references it cites were found in a registry or an index.

Targeting the Mitogen-Activated Protein Kinase Pathway: Physiological Feedback and Drug Response

Open access

Pratilas, Christine A., Solit, David B.·2010·Clinical Cancer Research

DOI 10.1158/1078-0432.ccr-09-3064PMC PMC2912210

Open this paper in CoChat — free account

Abstract

Mitogen-activated protein kinase (MAPK) pathway activation is a frequent event in human cancer and is often the result of activating mutations in the BRAF and RAS oncogenes. Targeted inhibitors of BRAF and its downstream effectors are in various stages of preclinical and clinical development. These agents offer the possibility of greater efficacy and less toxicity than current therapies for tumors driven by oncogenic mutations in the MAPK pathway. Early clinical results with the BRAF-selective inhibitor PLX4032 suggest that this strategy will prove successful in a select group of patients whose tumors are driven by V600E BRAF. Relief of physiologic feedback upon pathway inhibition may, however, attenuate drug response and contribute to the development of acquired resistance. An improved understanding of the adaptive response of cancer cells to MAPK pathway inhibition may thus aid in the identification of those patients most likely to respond to targeted pathway inhibitors and provide a rational basis for tailored combination strategies. Clin Cancer Res; 16(13); 3329–34. ©2010 AACR.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-09-3064

Cites

68 of 68 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
TGF-β SIGNAL TRANSDUCTION
Massagué, J. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.753 · Cited by 7,571
BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D. P., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P. W., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,060
PD 098059 Is a Specific Inhibitor of the Activation of Mitogen-activated Protein Kinase Kinase in Vitro and in Vivo
Alessi, D. R., Cuenda, A., Cohen, P., Dudley, D. T., & Saltiel, A. R. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.46.27489 · Cited by 3,374
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P., Garnett, M. J., Roe, S. M., Lee, S., Niculescu‐Duvaz, D., Good, V. M., Cancer Genome Project, Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,863
RAS oncogenes: the first 30 years
Malumbres, M., & Barbacid, M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1097 · Cited by 1,902
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikakos, P. I., Zhang, C., Bollag, G. E., Shokat, K. M., & Rosen, N. X. (2010) · Nature · doi:10.1038/nature08902 · Cited by 1,841
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Hatzivassiliou, G., Song, K. W., Yen, I., Brandhuber, B. J., Anderson, D. J., Alvarado, R., Ludlam, M. J. C., Stokoe, D., Gloor, S. L., Vigers, G. P. A., et al. (2010) · Nature · doi:10.1038/nature08833 · Cited by 1,649
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Heidorn, S. J., Milagre, C. S., Whittaker, S. R., Nourry, A., Niculescu‐Duvaz, I., Dhomen, N. S., Hussain, J., Reis-Filho, J. S., Springer, C. J., Pritchard, C. A., et al. (2010) · Cell · doi:10.1016/j.cell.2009.12.040 · Cited by 1,497
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer
Carracedo, A., Ma, L., Teruya-Feldstein, J., Rojo, F., Salmena, L., Alimonti, A., Egia, A., Sasaki, A. T., Thomas, G., Kozma, S. C., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34739 · Cited by 1,381

Show all 74 references

Research works printed but not linked: 1

Tsai, 2006, Development of a novel inhibitor of cogenic b-raf, Proc Amer Assoc Cancer Res, 47, 2412

Sorted by citations

Items 101–186 of 186

Mitogen-activated protein kinase signaling causes malignant melanoma cells to differentially alter extracellular matrix biosynthesis to promote cell survival
Afasizheva, A., Devine, A., Sheppard, H., Fung, K. L., Vieira, W. D., Blehm, B. H., Kotobuki, Y., Busby, B., Chen, E. I., & Tanner, K. (2016) · BMC Cancer · doi:10.1186/s12885-016-2211-7 · Cited by 18
Tumor reoxygenation following administration of Mitogen-Activated Protein Kinase inhibitors: A rationale for combination with radiation therapy
Karroum, O., Kengen, J., Danhier, P., Magat, J., Mignion, L., Bouzin, C., Verrax, J., Charette, N., Stärkel, P., Calderón, P. B., et al. (2012) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2012.05.005 · Cited by 19
The mutational profile of sporadic epithelial ovarian carcinoma.
Kalamanathan, S., Bates, V., Lord, R., & Green, J. A. (2011) · PubMed · Cited by 19
Extracellular signal-regulated kinase (ERK) expression and activation in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival
Theocharis, S. E., Kotta‐Loizou, I., Klijanienko, J., Giaginis, C., Alexandrou, P. T., Danas, E., Rodriguez, J., Patsouris, E., & Sastre‐Garau, X. (2014) · Tumor Biology · doi:10.1007/s13277-014-1853-9 · Cited by 19
Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas
Roller, D. G., Capaldo, B. J., Bekiranov, S., Mackey, A. J., Conaway, M. R., Petricoin, E. F., Gioeli, D. G., & Weber, M. J. (2015) · Oncotarget · doi:10.18632/oncotarget.6548 · Cited by 18
BRAF inhibitor therapy in HCL
Dietrich, S., & Zenz, T. (2015) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2015.10.001 · Cited by 18
Targeted inhibition of BRAF kinase: opportunities and challenges for therapeutics in melanoma
Pérez‐Lorenzo, R., & Zheng, B. (2011) · Bioscience Reports · doi:10.1042/bsr20110068 · Cited by 17
A quantitative structure-activity relationship (QSAR) study of some diaryl urea derivatives of B-RAF inhibitors
Hassanzadeh, F., Sadeghian-Rizi, S., & Sakhteman, A. (2016) · Research in Pharmaceutical Sciences · doi:10.4103/1735-5362.194869 · Cited by 17
MR‐detectable metabolic consequences of mitogen‐activated protein kinase kinase (MEK) inhibition
Lodi, A., Woods, S. M., & Ronen, S. M. (2014) · NMR in Biomedicine · doi:10.1002/nbm.3109 · Cited by 16
Histopathologic characteristics of therapy‐associated cutaneous neoplasms with vemurafenib, a selective BRAF kinase inhibitor, used in the treatment of melanoma
Sufficool, K. E., Hepper, D. M., Linette, G. P., Hurst, E. A., Lu, D., Lind, A. C., & Cornelius, L. A. (2014) · Journal of Cutaneous Pathology · doi:10.1111/cup.12346 · Cited by 15
The overview of Mitogen-activated extracellular signal-regulated kinase (MEK)-based dual inhibitor in the treatment of cancers
Wang, H., Chi, L., Yu, F., Dai, H., Si, X., Gao, C., Wang, Z., Liu, L., Zheng, J., Ke, Y., et al. (2022) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2022.116922 · Cited by 15
Identification of potential extracellular signal-regulated protein kinase 2 inhibitors based on multiple virtual screening strategies
Yang, R., Zhao, G., Zhang, L., Xia, Y., Yu, H., Yan, B., & Cheng, B. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1077550 · Cited by 14
Acquired resistance to molecularly targeted therapies for cancer
Stubbs, N. M., Roady, T. J., Schwermann, M. P., Eteshola, E. O. U., MacDonald, W., Purcell, C., Ryspayeva, D., Verovkina, N., Tajiknia, V., Ghandali, M., et al. (2025) · Cancer Drug Resistance · doi:10.20517/cdr.2024.189 · Cited by 18
Expression of RON in colorectal cancer and its relationships with tumor cell behavior and prognosis
Park, Y., Lee, G.-H., Kim, K., Myung, E., Kim, J., Myung, D., Park, K.-J., Cho, S. B., Lee, W., Jung, Y.-D., et al. (2012) · Tumori Journal · doi:10.1177/030089161209800517 · Cited by 14
Involvement of p38 mitogen‐activated protein kinase in acquired gemcitabine‐resistant human urothelial carcinoma sublines
Kao, Y., Hsu, W., Hu, H., Hsu, S., Lin, C., Chiu, C., Lu, C., Hour, T., Pu, Y., & Huang, A. (2014) · The Kaohsiung Journal of Medical Sciences · doi:10.1016/j.kjms.2014.03.004 · Cited by 14
PLX4032 resistance of patient-derived melanoma cells: crucial role of oxidative metabolism
Garbarino, O., Valenti, G. E., Monteleone, L., Pietra, G., Mingari, M. C., Benzi, A., Bruzzone, S., Ravera, S., Leardi, R., Farinini, E., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1210130 · Cited by 13
The KRAS signaling pathway's impact on the characteristics of pancreatic cancer cells
Chen, M., Chen, M., Fu, Y., & Zhang, J. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154603 · Cited by 12
Role and Function of Receptor Tyrosine Kinases in BRAF Mutant Cancers
Biersack, B., Tahtamouni, L. H., & Höpfner, M. (2024) · Receptors · doi:10.3390/receptors3010005 · Cited by 16
VX-11e protects articular cartilage and subchondral bone in osteoarthritis by inhibiting the RIP1/RIP3/MLKL and MAPK signaling pathways
Zhang, W., Zheng, X., Gong, Y., Jiang, T., Qiu, J., Wu, X., Lu, F., Wang, Z., & Hong, Z. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.105632 · Cited by 12
Evaluation of efficacy of a new MEK inhibitor, RO4987655, in human tumor xenografts by [18F] FDG-PET imaging combined with proteomic approaches
Tegnebratt, T., Ruge, E., Bader, S., Ishii, N., Aida, S., Yoshimura, Y., Ooi, C.-H., Lu, L., Mitsios, N., Méresse, V., et al. (2014) · EJNMMI Research · doi:10.1186/s13550-014-0034-6 · Cited by 11
Livin enhances tumorigenesis by regulating the mitogen-activated protein kinase signaling pathway in human hypopharyngeal squamous cell carcinoma
Kim, S., Yoon, T. M., Lee, D. H., Lee, J. K., Park, Y., Chung, I., Joo, Y., & Lim, S. C. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.5242 · Cited by 10
A human IgG-like bispecific antibody co-targeting epidermal growth factor receptor and the vascular endothelial growth factor receptor 2 for enhanced antitumor activity
Chen, Z., Xie, W., Acheampong, D. O., Xu, M., He, H., Yang, M., Li, C., Luo, C., Wang, M., & Zhang, J. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1121344 · Cited by 10
Kinase Inhibitors in Cancer
Mortlock, A. A., Foote, K. M., Kettle, J. G., & Aquila, B. M. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.11033-9 · Cited by 13
Cytopathological Diagnosis of Non Small Cell Lung Cancer: Recent Advances Including Rapid On-Site Evaluation, Novel Endoscopic Techniques and Molecular Tests
Soccal, M. P. P. M. (2013) · Journal of Pulmonary & Respiratory Medicine · doi:10.4172/2161-105x.s5-002 · Cited by 10
Endogenous Molecular-Cellular Network Cancer Theory: A Systems Biology Approach
Wang, G., Yuan, R., Zhu, X., & Ao, P. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7456-6_11 · Cited by 9
FGFR-mediated ERK1/2 signaling contributes to mesendoderm and definitive endoderm formation in vitro
Lau, H. H., Amirruddin, N. S., Loo, L. S. W., Chan, J. W., Iich, E., Krishnan, V. G., Hoon, S. S., & Teo, A. K. K. (2023) · iScience · doi:10.1016/j.isci.2023.107265 · Cited by 9
Mediator kinase inhibition impedes transcriptional plasticity and prevents resistance to ERK/MAPK-targeted therapy in KRAS-mutant cancers
Nussbaum, D. P., Martz, C. A., Waters, A. M., Barrera, A., Liu, A., Rutter, J. C., Cerda-Smith, C. G., Stewart, A. E., Wu, C., Çakır, M., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00615-9 · Cited by 10
[18 F]FDG-PET imaging is an early non-invasive pharmacodynamic biomarker for a first-in-class dual MEK/Raf inhibitor, RO5126766 (CH5126766), in preclinical xenograft models
Tegnebratt, T., Lu, L., Lee, L., Méresse, V., Tessier, J. J. L., Ishii, N., Harada, N., Pisa, P., & Stone‐Elander, S. (2013) · EJNMMI Research · doi:10.1186/2191-219x-3-67 · Cited by 9
Spontaneous splenic rupture in patient with metastatic melanoma treated with vemurafenib
Castellani, E., Covarelli, P., Boselli, C., Cirocchi, R., Rulli, A., Barberini, F., Caracappa, D., Cini, C., Desiderio, J., Burini, G., et al. (2012) · World Journal of Surgical Oncology · doi:10.1186/1477-7819-10-155 · Cited by 9
Vx-11e protects against titanium-particle-induced osteolysis and osteoclastogenesis by supressing ERK activity
Li, C., Wu, Z., Yuan, G., Fang, Z., Lin, X., Pu, R., Kang, Y., Li, L., Shao, S., Ding, J., et al. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.05.054 · Cited by 9
Multimodal imaging of tumor response to sorafenib combined with radiation therapy: comparison between diffusion‐weighted MRI, choline spectroscopy and 18F‐FLT PET imaging
Karroum, O., Mignion, L., Kengen, J., Karmani, L., Levêque, P., Danhier, P., Magat, J., Bol, A., Labar, D., Grégoire, V., et al. (2013) · Contrast Media & Molecular Imaging · doi:10.1002/cmmi.1525 · Cited by 8
Are oncogenes sufficient to cause human cancer?
Woodman, S. E., & Mills, G. B. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1015563107 · Cited by 8
The Dynamics of the Cell Signaling Network; Implications for Targeted Therapies
Gioeli, D. G. (2011) · Humana Press eBooks · doi:10.1007/978-1-60761-478-4_2 · Cited by 7
Genomic and transcriptomic profiles and in vitro resistance to mitoxantrone and idarubicin in pediatric acute leukemias
Laskowska, J., Lewandowska‐Bieniek, J., Szczepanek, J., Styczyński, J., & Tretyn, A. (2016) · The Journal of Gene Medicine · doi:10.1002/jgm.2889 · Cited by 7
The end of KRAS, and other, cancers? A new way forward
Mallucci, L., & Wells, V. E. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.11.018 · Cited by 6
Patients with BRAF-Mutant Advanced/Metastatic Melanoma: Original Research on the Treatment Reality in Germany and Austria in the Era of Choice
Haferkamp, S., Alter, M., Debus, D., Schilling, B., Pinter, A., Terheyden, P. A. M., Utikal, J. S., Sachse, M., Haalck, T., & Wolf, I. H. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01430-x · Cited by 6
PPARγ acetylation governs mammary adenocarcinoma tumor growth via acetylated residues that determine DNA sequence-specific binding
Tian, L., Jiao, X., Wang, C., Li, D., Ertel, A., Achinger-Kawecka, J., Addya, S., Soccio, R. E., Chen, E. R., Győrffy, B., et al. (2025) · Oncogene · doi:10.1038/s41388-025-03492-z · Cited by 5
Involvement of LOC66273 isoform 2 a novel Mth938 containing protein in MAPK pathway
Ma, X. (2011) · Frontiers in Bioscience-Elite · doi:10.2741/e327 · Cited by 5
RAF, MEK and ERK Inhibitors as Anti-Cancer Drugs: Intrinsic and Acquired Resistance as a Major Therapeutic Challenge
Maik-Rachline, G., Cohen, I., & Seger, R. (2018) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-67932-7_5 · Cited by 5
Targeted Therapy in Pediatric Langerhans Cell Histiocytosis: Describing a Novel Strategy to Minimize Long‐Term Exposure While Maintaining Efficacy
Wojciechowska, N., Richards, A. E., Anthony, A., Diaz, M., Vallance, K., Greer, C., & Ray, A. (2025) · Pediatric Blood & Cancer · doi:10.1002/pbc.32016 · Cited by 4
ERK/pERK expression, B-raf and K-ras mutations in colon adenocarcinomas: correlation with clinicopathological characteristics and expression of hMLH1 and hMSH2.
Levidou, G., Saetta, A. A., Gigelou, F., Κάρλου, Μ., Papanastasiou, P., Stamatelli, A., Kavantzas, N., Michalopoulos, N. V., Agrogiannis, G. D., Patsouris, E., et al. (2012) · World Journal of Surgical Oncology · doi:10.1186/preaccept-1032136556616351 · Cited by 4
Sensitization of (colon) cancer cells to death receptor related therapies
Pintzas, A., Zhivotovsky, B., Workman, P., Clarke, P. A., Linardopoulos, S., Martinou, J., Lacal, J. C., Robine, S., Nasioulas, G., & Anděra, L. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.19600 · Cited by 4
DCT015, a new sorafenib derivate, inhibits tumor growth and angiogenesis in gastric cancer models
Wang, W., Wang, H., Ni, Y., Yao, Z., Ye, L., & Tian, J. (2016) · Tumor Biology · doi:10.1007/s13277-016-4826-3 · Cited by 4
MAPK Inhibition Requires Active RAC1 Signaling to Effectively Improve Iodide Uptake by Thyroid Follicular Cells
Faria, M., Domingues, R., Bugalho, M. J., Matos, P., & Silva, A. L. (2021) · Cancers · doi:10.3390/cancers13225861 · Cited by 4
Intracellular Signaling
Hanrahan, A. J., Iyer, G., & Solit, D. B. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-2865-7.00002-3 · Cited by 5
Self-citation
Oil and derivatives
Sadauskas‐Henrique, H., de Souza-Bastos, L. R., & da Silva, G. S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821337-7.00001-3 · Cited by 3
Intracellular Signaling
Hanrahan, A. J., Iyer, G., & Solit, D. B. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00002-5 · Cited by 5
Self-citation
Novel compound ZCJ14, a gefitinib analog, exhibited prominent anti-cancer effect among several cancer cell lines
Wang, J., Yan, P., Wang, H., Zuo, S., Zhang, S., Cao, Y.-X., & Cao, L. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120875 · Cited by 3
The Therapeutic Promise of Anti-Cancer Drugs Against the Ras/Raf/MEK/ERK Pathway
(2013) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9781608051366113020006 · Cited by 3
Design and Synthesis of Novel MEK Inhibitors for the Treatment of Solid Tumors
Zeng, J., Luo, Z., Zhao, T., Xia, C., Liu, F., Li, N., Qu, L., & Wang, C. (2025) · Chemical Biology & Drug Design · doi:10.1111/cbdd.70067 · Cited by 1
Dual-specific phosphatase 5 (DUSP5), upregulated in lung adenocarcinoma, as a potential therapeutic target for lung cancer
Kawabe, N., Komeda, K., Muraki, N., Sunaga, N., Taguchi, A., Iwabe, A., Minna, J. D., Tanaka, I., Matsushima, M., Kawabe, T., et al. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152595 · Cited by 1
A Chemically Inducible Multimerization System for Tunable and Background-Free RTK Activation
Zheng, Y., Fei, J., Chakrabarti, A., & Zhou, R. (2026) · Analytical Chemistry · doi:10.1021/acs.analchem.5c05190 · Cited by 1
Signalisation cellulaire et cancer : caractérisation de cibles thérapeutiques
de Crémoux, P., & Robert, J. (2012) · Pathologie Biologie · doi:10.1016/j.patbio.2012.05.006 · Cited by 1
Breaking barriers: Pembrolizumab's role in overcoming targeted therapy resistance in BRAF-mutant melanoma
Idris, O. A., Shebrain, A., Jawad, A., Pacione, S. C., Haj, D., Bzizi, H. F., Ahmedfiqi, Y. O., Jahromi, B. S., Deleon, N., Zhang, T., et al. (2025) · Clinical Surgical Oncology · doi:10.1016/j.cson.2025.100095 · Cited by 1
Mediator Kinase Inhibition Impedes Transcriptional Plasticity and Prevents Resistance to ERK/MAPK-Targeted Therapy in KRAS -Mutant CancersPreprint
Nussbaum, D. P., Martz, C. A., Waters, A. M., Barrera, A., Rutter, J. C., Cerda-Smith, C. G., Stewart, A. E., Wu, C., Çakır, M., Levandowski, C. B., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.17.508384 · Cited by 1
RAF isoform selectivity of MEK inhibitors and rational design of a covalent ARAF-MEK inhibitorPreprint
Chakraborty, S., Jiang, J., Viñals, J., Gazgalis, D., Gero, T. W., Tavares, M. T., Dittemore, G. A., Tkacik, E., Jang, D. M., Ha, B. H., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.15.693503 · Cited by 1
Advances in the Development of EGFR Targeted Therapies for the Treatment of Glioblastoma
Johns, T. G. (2012) · InTech eBooks · doi:10.5772/21606
Prerequisite Genetic Traits for Metastasis
Faingold, D., Russell-Hermanns, D. S., & Bakalian, S. (2013) · Springer eBooks · doi:10.1007/978-1-4614-3685-0_27
Prädiktive Biomarker tumorrelevanter Signalwege in der molekularen Pathologie
Bonzheim, I., & Fend, F. (2014) · Der Pathologe · doi:10.1007/s00292-013-1798-6
Title New druggable targets in the Ras pathway
Crespo, P. (2016)
Pulmonary-Respiratory Medicine
Tonn, H. (2001) · JAMA · doi:10.1001/jama.285.7.943-jbk0221-3-1
BRAF mutations in human cancer: biologic and therapeutic implications
Nissan, M. H., & Solit, D. B. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139046947.023
Self-citation
Preclinical pharmacokinetic and pharmacodynamic evaluation of new anticancer agents for brain tumor chemotherapy
Nuthalapati, S. (2012) · TUScholarShare (Temple University)
Advances in biological treatment of melanoma
Shah, Q. S. I., Wan, X., Sulaiman, A., Abliz, P., Butt, Y., & Jin, L. (2018) · International Journal of Research in Dermatology · doi:10.18203/issn.2455-4529.intjresdermatol20180426
Principles of Targeted Therapy
Bollag, G. E., & Flaherty, K. T. (2018) · Springer eBooks · doi:10.1007/978-1-4614-7322-0_35-1
Quantitative Analysis of the Rewiring of Signaling Pathways to Alter Cancer Cell Fate
Schmitz, R. M., Willerth, S. M., van Rensburg, G., & Edwards, R. (2019) · Journal of Medical and Biological Engineering · doi:10.1007/s40846-019-00489-4
Exploring tsRNA Function in Aggressive Breast Cancer Cell Models
Adams, C. E. (2020) · ScholarWorks -A service of University of Vermont Libraries (University of Vermont)
Moléculas moduladoras de vías de señalización basales y desencadenadas por el Factor de Crecimiento Derivado de Plaquetas (PDGF) en un modelo celular de fibrosarcoma humano
Grismaldo, A., & Morales, L. (2018) · Revista de Nutrición Clínica y Metabolismo · doi:10.35454/rncm.v1n1.076
Investigação do potencial antineoplásico de diferentes classes de inibidores da via IGF1R-IRS1/2 em neoplasia mieloproliferativa
Fernandes, J. C. (2021) · doi:10.11606/t.17.2021.tde-08092021-135736
Targeted Therapies
Kessler, E. R., Brittain, P., Davis, S. L., Leong, S., Eckhardt, S. G., & Lieu, C. H. (2017) · doi:10.1002/9781119468868.ch21
Divergent MEK/ERK and AMPK signaling dictate lipogenic plasticity and dependence on fatty acid synthesis in GlioblastomaPreprint
Eyme, K. M., Sammarco, A., Jha, R., Mnatsakanyan, H., Neustadt, R., Moses, C., Alnasser, A. A., Tardiff, D. F., Su, B., Williams, K. J., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.04.07.487530
Transcriptomic Alterations Induced By Vemurafenib after Treatment of Melanoma: A Comprehensive Bioinformatics Analysis
Xie, J., Cao, Y., Zhu, Z., Ruan, S., Wang, M., & Shi, J. (2021) · Indian Journal of Pharmaceutical Sciences · doi:10.36468/pharmaceutical-sciences.spl.351
Principles of Targeted Therapy
Bollag, G. E., & Flaherty, K. T. (2019) · Springer eBooks · doi:10.1007/978-1-4614-7147-9_35
Dual Targeting of Matrix Metalloproteases and the MAPK Pathway in Acute Myeloid Leukemia Cells Using an MMP-activated anthrax lethal toxin (PrAgL1/LF). (c2020)
Saneh, A. A. (2020) · doi:10.26756/th.2022.333
A Subungual Nevoid Melanoma of the Right Hallux from a 65-Year-Old Man: A Case Report
Quist, M., Yim, J. H., Mirkin, G. S., & Hao, X. (2023) · Journal of the American Podiatric Medical Association · doi:10.7547/21-108
Ciblage tumoral du récepteur HER3 à l’aide d’anticorps : vers de nouvelles pistes thérapeutiques
Lazrek, Y. (2013) · doi:10.70675/6783b8c7z73fbz412fzbcf1zf4d15d96dd04
Etude de l'expression de recombinases néogéniques dans le cancer colorectal
Arnaoty, A. (2013) · theses.fr (ABES) · doi:10.70675/ae2c888dz8452z40efz92a9z667ad8e674b4
Mécanismes de résistance aux thérapies ciblées du mélanome : implication du facteur de transcription Aryl hydrocarbon Receptor
Tardif, N. (2019) · theses.fr (ABES) · doi:10.70675/3578ec97z89f3z41dfz8a68zf1d1d099db63
Étude de la fonction transcriptionnelle de la parkine dans les cancers cérébraux
Rouland, L. (2019) · theses.fr (ABES) · doi:10.70675/144669dcz5f62z47dcz9bd6z551bd742d8f9
Nucleoporin TPR integrates MAPK signaling with mitogen-induced transcriptional programs
Liu, J., Zheng, Y., Xiong, Y., Ma, R., Lin, Z., Lin, H., Andújar-Sánchez, M., Bártková, J., Liu, J., Foiani, M., et al. (2026) · Cell Death and Disease · doi:10.1038/s41419-026-08760-8 · Cited by 2
Molecular Design and Anticancer Activities of Small‐Molecule BRAF Inhibitors: A Medicinal Chemistry Perspective
Jia, S., Lin, J., Wu, J., Xu, H., Zeng, Q., Liu, M.-P., & Shen, J. (2026) · Drug Development Research · doi:10.1002/ddr.70389
RAF isoform selectivity of MEK inhibitors and rational design of a covalent ARAF-MEK inhibitor
Chakraborty, S., Jiang, J., Camallonga, J. V., Gazgalis, D., Gero, T. W., Tavares, M. T., Dittemore, G. A., Tkacik, E., Beyett, T. S., Jang, D. M., et al. (2026) · Science Advances · doi:10.1126/sciadv.aee5241 · Cited by 2
Introduction to breast cancer and signaling pathways
Çifçi, K. U., Sağır, Ş., & Tutar, Y. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-49074-3.00001-7
BindingDB Entry 50015760: The overview of Mitogen-activated extracellular signal-regulated kinase (MEK)-based dual inhibitor in the treatment of cancers.
BindingDB (2023) · UC San Diego · doi:10.7270/q2dr30fw
BindingDB Entry 50002489: First SAR Study for Overriding NRAS Mutant Driven Acute Myeloid Leukemia.
BindingDB (2020) · UC San Diego · doi:10.7270/q2t72m31
BindingDB Entry 50009837: Discovery of 1-(1H-Pyrazolo[4,3-c]pyridin-6-yl)urea Inhibitors of Extracellular Signal-Regulated Kinase (ERK) for the Treatment of Cancers.
BindingDB (2021) · UC San Diego · doi:10.7270/q2j969vw

Authors: Pratilas, C. A., & Solit, D. B.
Affiliations: Memorial Sloan Kettering Cancer Center (US)
Corresponding author: Solit, David B.
ORCID: Pratilas, Christine A.
Solit, David B.
Venue: Clinical Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2010-06-30
Volume: 16
Issue: 13
Pages: 3329-3334
ISSN: 1078-0432 (ISSN-L)
1557-3265
DOI: 10.1158/1078-0432.ccr-09-3064
PMC: PMC2912210
OpenAlex: W2079576402
Cited by: 183
References: 74
Citations by year: 2026: 5 · 2025: 7 · 2024: 2 · 2023: 7 · 2022: 7 · 2021: 6 · 2020: 5 · 2019: 9 · 2018: 9 · 2017: 9 · 2016: 14 · 2015: 9 · 2014: 17 · 2013: 21 · 2012: 20
FWCI: 2.13
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Clinical Cancer Research (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (R01CA127240, K08CA127350, P30CA008748, P50CA092629)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
Keywords: MAPK signaling, BRAF V600E mutation, RAS mutations, BRAF inhibitors, vemurafenib, physiological feedback, acquired drug resistance, targeted therapy, combination therapy, predictive biomarkers
MeSH terms: Antineoplastic Agents, Humans, Neoplasms, Genes, ras, Signal Transduction, Drug Delivery Systems, Mitogen-Activated Protein Kinases, Feedback, Physiological, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Targeting the Mitogen-Activated Protein Kinase Pathway: Physiological Feedback and Drug Response

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks